STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
PCI
CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS
Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More
AGENT IDE: Paclitaxel-Coated Balloon for ISR
The AGENT IDE Trial: Revolutionizing the Treatment of In-Stent Restenosis The AGENT IDE Trial, a prominent study published in 2024, has shed light on a pivotal question in cardiology: Is a paclitaxel-coated balloon more effective than an uncoated balloon for … Read More
ILUMIEN IV: OCT-Guided vs. Angio-Guided PCI
Unveiling the ILUMIEN IV Trial: A New Era of Percutaneous Coronary Intervention The ILUMIEN IV: OPTIMAL PC Trial, conducted in 2023, is a landmark study that compares the efficacy of Optical Coherence Tomography (OCT)-guided coronary stent implantation to the traditional … Read More
OCTOBER Trial: OCT in Complex PCI
The OCTOBER trial, detailed in the New England Journal of Medicine in 2023, was a multicenter, randomized, open-label trial designed to assess the effectiveness of optical coherence tomography (OCT) in guiding percutaneous coronary intervention (PCI) for the treatment of complex … Read More
FIRE Trial: Complete PCI in MI in Older Patients
The FIRE trial, published in the New England Journal of Medicine in 2023, was a multicenter, randomized controlled trial that aimed to evaluate the benefits of complete revascularization versus culprit-lesion-only percutaneous coronary intervention (PCI) in older patients (≥75 years of … Read More
ORBITA-2 Trial: PCI in Stable Angina
Understanding the Impact of PCI in Stable Angina: Insights from the ORBITA-2 Trial The ORBITA-2 trial has emerged as a cornerstone study in the field of cardiology, particularly in the treatment of stable angina through Percutaneous Coronary Intervention (PCI). This … Read More
WOEST Trial Summary: Clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing PCI
WOEST Trial Summary The WOEST trial, a groundbreaking study published in The Lancet, has shed light on a significant issue faced by patients undergoing percutaneous coronary intervention (PCI) while taking oral anticoagulants. Traditionally, triple therapy involving aspirin and clopidogrel has … Read More
BRIGHT-4 Trial Summary: Bivalirudin in STEMI
2022 BRIGHT-4 TRIAL Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with STEMI undergoing primary PCI investigator-initiated, open-label, randomized controlled trial Objective: To evaluate the safety and efficacy of a high-dose infusion of bivalirudin after primary percutaneous coronary … Read More
SECURE PCI Trial Summary: Loading Atorvastatin in ACS
2018 SECURE-PCI TRIAL Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome double-blind, multicenter, randomized controlled trial Objective: To determine if periprocedural loading doses of atorvastatin decrease 30-day … Read More